MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, BCAX had $226,777K increase in cash & cash equivalents over the period. -$37,568K in free cash flow.

Cash Flow Overview

Change in Cash
$226,777K
Free Cash flow
-$37,568K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance on common...
    • Proceeds from maturities and sal...
    • Accounts payable and accrued exp...
    • Others
Negative Cash Flow Breakdown
    • Accounts payable and accrued exp...
    • Operating lease liabilities
    • Purchase of property and equipme...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-56,211 -37,386 -36,330 -64,234
Stock-based compensation
5,858 4,449 3,614 6,943
Depreciation
44 43 24 38
Non-cash lease expense
273 297 249 349
Net amortization of premiums and discounts on marketable securities
-338 -269 -32 -
Prepaid expenses and other assets
-2,089 -839 301 -4,743
Accounts payable and accrued expenses-Nonrelated Party
11,725 6,423 3,949 -2,715
Accounts payable and accrued expenses-Related Party
-1,354 1,472 -168 1,499
Operating lease liabilities
-270 -292 -317 -323
Net cash used in operating activities
-37,508 -23,886 -29,248 -53,700
Proceeds from sale of property and equipment
-0 0 0
Purchases of marketable securities
-82,094 236,079 -
Proceeds from maturities and sales of marketable securities
101,000 ---
Purchase of property and equipment
60 238 42 0
Net cash provided by investing activities
100,940 -82,332 -236,121 0
Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs
161,763 29,498 0 -
Proceeds from exercise of options
1,582 1,732 436 595
Payment for deferred offering costs
---0
Net cash provided by financing activities
163,345 31,230 436 595
Net (decrease)/increase in cash and cash equivalents
226,777 -74,988 -264,933 -53,105
Cash and cash equivalents at beginning of period
96,685 171,673 489,711 -
Cash and cash equivalents at end of period
323,462 96,685 171,673 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance oncommon stock and...$161,763K Proceeds from exercise ofoptions$1,582K Proceeds from maturitiesand sales of...$101,000K Net cash provided byfinancing activities$163,345K Net cash provided byinvesting activities$100,940K Canceled cashflow$60K Net(decrease)/increase in cash and cash...$226,777K Canceled cashflow$37,508K Purchase of property andequipment$60K Accounts payable andaccrued...$11,725K Stock-based compensation$5,858K Prepaid expenses andother assets-$2,089K Net amortization ofpremiums and discounts on...-$338K Non-cash lease expense$273K Depreciation$44K Net cash used inoperating activities-$37,508K Canceled cashflow$20,327K Net loss-$56,211K Accounts payable andaccrued...-$1,354K Operating leaseliabilities-$270K

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. (BCAX)